Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Goblet-1 trial pancreatic trial -> COMPLETE RESPONSE !

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 06, 2022 10:59am

111 Views

Post# 35153344

RE:RE:RE:ONCY Goblet-1 trial pancreatic trial -> COMPLETE RESPONSE !

Reposted : The unfolding process towards an M&A : Fast track designations (announced) -> Type C Meetings -> Partnership/Acquisition -> Regulatory Filing

Noteable - (11/10/2022 10:08:57 AM)

RE:ONCY Goblet-1 trial pancreatic trial -> COMPLETE RESPONSE !

“I think all of this sets us up for regulatory filings, Type C meetings and hopefully, Fast Track breakthrough designations," Coffey said, adding that Oncolytics is hoping to get a partnership in place next year (2023) to expedite the development and get the medicine to patients sooner.

https://www.biospace.com/article/following-promising-data-oncolytics-plans-to-move-pancreatic-cancer-therapeutic-into-phase-iii/

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario